Dr. Bandar Al Knawy holds the position of Chief Executive Officer (CEO) at Health Affairs, Ministry of National Guard, an organization which comprises five medical cities in the five major regions of Saudi Arabia as well as holding the position of President, King Saud bin Abdulaziz University for Health Sciences, since February 2009. He also served as the General Supervisor for the Royal Clinics of the late King Abdullah Bin Abdulaziz Al Saud, Custodian of the Two Holy Mosques from 2009 until January, 2015.

He obtained his MBBS from King Abdulaziz University, Jeddah, Faculty of Medicine in June 1985. He completed his residency training in Internal Medicine in 1990 and obtained his Gastroenterology Fellowship in 1992 from Dalhousie University, Halifax, Nova Scotia, Canada. He holds a fellowship in Internal Medicine from the American and Canadian Boards, as well as the American Board Certification in Gastroenterology.

He is a strong advocate of Quality and Patient Safety and pioneered the development of the Medication Safety Program in Saudi Arabia in addition to many Patient Safety initiatives at NGHA, and was responsible in the recent commissioning of major healthcare expansions at NGHA, including, King Abdullah International Medical Research Center, King Abdullah Specialized Children Hospital and King Abdullah bin Abdulaziz International Foundation for Humanitarian Activities, and the inception of the system-wide EMR. He currently represents MNGHA at the National Health Services Council.

He has had numerous scientific and medical articles published in international journals. He is the guest editor of the February 2010 issue of Clinics in Liver Disease – Healthcare Associated Transmission of Hepatitis B & C Viruses. Dr Al Knawy is the author of a book entitled “Hepatology: A Practical Approach”, published in December 2004, and a textbook entitled Hepatocellular Carcinoma: A Practical Approach”, released in September 2009.

He is a highly skilled and qualified medical professional who is committed to provide, with all sincerity and dedication, the highest quality patient care for the betterment and the development, of National Guard Health Affairs.

Dr. Ahmed Alaskar is a Consultant and Associate Professor, Adult Hematology & Stem Cell Transplantation, King Abdulaziz Medical City, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs. He is also the Executive Director, King Abdullah International Medical Research Center and the President of Saudi Society of Blood and Marrow Transplantation (SSBMT).

Dr. Alaskar gained his MBBS from King Saud University and completed medical trainings at University of British Columbia, Vancouver, Canada where he obtained both the Canadian and the American Boards of Internal Medicine and of Hematology and Stem Cells Transplantation.

Dr. Alaskar assumed numerous administrative tasks and positions since 2001. He was the Director, Inpatient Services at King Abdulaziz Medical City – Riyadh and the Program Director of the Saudi Board Preparatory Course for Internal Medicine. He led the Department of Oncology at its establishment stage in 2005/2006 while he continued to be the Head, Division of Adult Hematology & Hematopoietic Stem Cell Transplantation until March 2015. He was one of the founders of the Saudi Scientific Society of Blood and Marrow Transplantation in the Kingdom of Saudi Arabia and was elected twice to be the President of the society. He was then appointed as Deputy Executive Director, King Abdullah International Medical Research Center from May 2010 and became the Executive Director in September 2013 until present.

Dr. Alaskar has a number of publications and involved in numerous local and national committees and member of several International Societies.

Dr. Haoudi is currently leading the Strategy and Business Development and is also Managing Director of the Biotechnology Park at King Abdullah International Medical Research Center at the Ministry of National Guard Health Affairs, and is also Distinguished Scholar at Harvard University/Boston Children’s Hospital.
Dr. Haoudi is an international Research & Development and Innovation Executive with over 25 years experience, having held several senior positions in Research and Development and Innovation, including Founding Vice President for Research and Executive Director for R&D and Managing Director for Biotechnology Industrial Park. Vast experience in science and technology policy development, strategy and Business development, Review and Assessment, feasibility studies and Corporate Development and International Partnerships Development.

Dr. Haoudi held several senior and prestigious positions in the academia, government and private sectors. Dr. Haoudi was also Research Professor of cancer and infectious diseases at the University of Virginia and Eastern Virginia Medical School and a fellow of the US National Institutes of Health. He has also held several other positions in elite research and education institutions including Visiting Professor at Harvard Medical School (USA) and a fellow at Institut Pasteur (France) and had served as consultant and advisor to several biotechnology and pharmaceutical companies.

Dr. Haoudi was elected as a member of the Royal Academy for Sciences and Technology since 2006 and graduated from University Paris XI and Paris VI, France in 1996 with a doctoral degree in cellular and molecular genetics and received executive education from Harvard Business School in Corporate Management and Strategy and Intellectual Property.

Zayd Alathari, Juris Doctor, MS, BS

Senior Manager Intellectual Property Counsel, Legal Affairs

Saudi Basic Industries Corporation (SABIC)

Zayd Alathari joined SABIC in February 2012 and is based in Riyadh.  He is responsible for a team of attorneys and IP practitioners handling all aspects of intellectual property work for a number of Business Units, Manufacturing and Technology & Innovation teams in developing and implementing IP strategy, providing legal and IP counseling and contract support to enhance the value of SABIC technology.  The team’s responsibilities include advising on, drafting and negotiating technology related agreements and patent portfolio management, patent preparation, prosecution and maintenance, freedom-to-practice, patent litigation and IP due diligence.

Amit heads IQVIA’S business in Africa, Middle East and South Asia and has led the company’s operations in the region since 2012. He has been pivotal in providing healthcare customers end-to-end management of their commercial, clinical and operational functions.

Amit co-founded PharmARC, a provider of analytics services to global healthcare companies spread across India, Europe and the US. He joined IQVIA with the sale of the 300 people strong PharmARC to IQVIA (then IMS Health) in January 2012.

Experience: Amit has over two decades of experience in driving commercial healthcare engagements at global and regional levels. He has worked with large manufacturers, payors, providers, government and donor agencies in varied analytics, consulting and technology engagements across the globe. Prior to co-founding PharmARC, he worked with MNCs such as F. Hoffman La Roche and Bristol-Myers Squibb.

Education: Amit holds a master’s degree in Statistics and bachelor’s in Mathematics from the New Jersey Institute of Technology, NJ.

Chief Operating Officer, Technlology Development and Investment Company (TAQNIA)

Abdulelah Alnemr is currently the Chief Operating Officer at The Saudi Technology Development and Investment Company (TAQNIA) a wholly owned subsidiary of the Saudi Public Investment Fund (PIF) that is mandated on investing in local and international technologies and developing them into commercially viable enterprises.

Abdulelah has 15 years of experience and filled executive positions, business and project development, stategy, creating partnerships, corporate investment banking, and project financing.

Prior to joining TAQNIA, Abdulelah worked at Riyad Capital corporate investment banking division as an Assistant Vice President and at the Saudi Industrial Development Fund (SIDF) as a lending team leader.

He has led and contributed to the closure of several successful debt and equity transactions, advised and evaluated greenfield and brownfield industrial projects across different sectors including health care, building materials, pertochemicals, defense, research and development, technology investment with a total value of around SAR 15 billion.

He has completed numerous training programs including the executive development program from Wharton Business School.

Abdulelah obtained his bachelor degree in Finance & Economics with distinction from King Fahd University of Petroleum & Minerals.

CURRENT PROFILE OF PROF. ADEEL CHAUDHARY

• Professor of Human Molecular Biology at Medical Laboratory Technology Department, Faculty of Applied Medical Sciences [FAMS], KAU, Since 2016
• Director for the Center of Innovation in Personalized Medicine [CIPM], KAU since 2017
• Head of the research center bioethics committee registered with national Bioethics board at King Abdulaziz City for Science & Technology [KACST], Riyadh
• Member of King Abdulaziz University academic promotion committee
• Consultant at GenaTi diagnostic services, KAU, since 2019

PREVIOUS POSITIONS

• Vice dean for Development at Faculty of Applied Medical Sciences, 2013-2017
• Assistant vice director King Fahd Medical Research Center, 2012-2014
• Head of Clinical Radiology Department at Faculty of Applied Medical Sciences [FAMS], 2010-2012
• Member of research committee in health sciences at KACST until 2014-2015
• Established Diagnostic Genomic Medicine Unit, KAU, 2003-2008
• Vice-director for Technical Affairs at the Center of Excellence in Genomic Medicine Research [CEGMR], KAU, 2008-2018

BRIEF SYNOPSIS

After completing PhD in 1999 from the University of Sheffield, UK which focused on developing the first TaqManTM system for allelic differentiation in collaboration with Perkin Elmer, Dr. Adeel played key role in establishing applied genomics research in Saudi Arabia. He contributed to establishing diagnostic Genomic Medicine unit at KAU that went on to becoming a Centre of Excellence in Genomic Medicine Research. All the way from implying automated Sanger sequencing to investigate malignant tumors in 2004 to establishing array CGH for studying intellectual disabilities in 2009; from hosting NGS in 2009 to 10x Genomics in 2019, a dynamic career and professional leadership remained hallmarks of Dr. Adeel. Since 2017, as director of CIPM at KAU, the focus is on restructuring the research groups while steering the previously established units at this centre into proactive diagnostic service providers. IVF and Pre-Implantation Genetic Diagnosis units now provide advanced services in coordination with our first commercial arm GenaTi based at KAU. Keen interest in developing innovative therapeutics implying gene editing, epigenomics, immunomics, 3D bio-printing and tissue engineering, iPSC and gene editing are top priority and this will only be achieved by initiating and sustaining Inter-
institutional multidisciplinary teamwork. Also, supervise undergraduate and MSc as well as national and international PhD students registered with KAU.

PERSONAL RESEARCH AND ACADEMIC INTERESTS:

Principle investigator and co-investigator on several projects addressing autism, intellectual disabilities, targeted drug therapy in Meningeomas, customized chip development for Breast Cancer susceptibility genes, duchenne muscular dystrophy, spinal muscular atrophy, juvenile myoclonic epilepsy and more recently microcephaly.

Apart from research as a Professor of Human Molecular Genetics; Dr. Adeel continues to deliver his academic responsibilities at the Faculty of Applied Medical Sciences, supervise postgraduate students, organize expert lectures, establish PhD program in Medical Laboratory Technology. He successfully hosted first Mawhiba program in coordination with MoE for the extraordinary gifted and talented young Saudi students which later on won ISEF- Intel awards.

Director of the University Sleep Disorders Center, College of Medicine, King Saud University

• Established the First Academic Sleep Disorders Center in Saudi Arabia and the Gulf Area.
• The Founder of the Fundamental Critical Care Support (FCCS) course in the region.
• Founding member of the Saudi Thoracic Society and a member of the board of directors.
• Associate Editor, Ann Thoracic Med journal http://www.thoracicmedicine.org/
• Associate Editor, Frontiers in Sleep and Chronobiology
• Ex-International Governor, American College of Chest Physicians (ACCP) in Saudi Arabia (2000-2006).
• Published around 130 papers in peer reviewed journals and around 25 book chapters

Specialties:

• Sleep Medicine
• Pulmonary Medicine
• Critical Care Medicine
• Internal Medicine

Dr. Suliman Alghnam is the head of the population health department at King Abdullah International Medical Research Center (KAIMRC). His background is in rehabilitation and physiotherapy and after obtaining his doctoral degree from the University of Wisconsin-Madison, Dr. Alghnam completed a postdoctoral fellowship in trauma outcomes at Johns Hopkins Bloomberg School of Public Health. His research focuses on health outcomes of patients after traumatic injuries. He is experienced in analyzing nationally representative samples and estimating national statistics for health measures. His interests also include the global burden of injuries and trauma center improvement in developing countries. He published 30 papers in peers-review journals and presented in more than 20 national and international conference.

Dr. Naif Khalaf Alharbi is a virologist and vaccinologist at KAIMRC, MNG-HA, Riyadh. He has attained his BSc in Medical Microbiology (Qassim University), MSc in Molecular Medical Microbiology (University of Nottingham), and DPhil in Molecular Virology and Vaccinology (University of Oxford). He spent his postdoctoral fellowship in the Jenner Institute, University of Oxford, where he developed ChAdOx MERS, a novel vaccine against MERS-CoV, that is now heading to phase I clinical trial. Dr. Alharbi has published high impact research articles on the development of vaccine viral vectors, such as Modified Vaccinia virus Ankara and has filed a patent with his Oxford collaborators on the development. At KAIMRC, Dr. Alharbi is a PI on a vaccine development grant and his research interest is focused on vaccines against emerging pathogens and on studying viruses that are of importance to the Kingdom of Saudi Arabia and the Middle East region.

Coming soon

Chairman, Intensive Care Department, Medical Director, Respiratory Services, Professor, College
of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City
Riyadh, Kingdom of Saudi Arabia.

Dr. Arabi obtained his Internal Medicine Training at Wayne State University, Detroit, MI, USA (1992-1994), then he was the Chief Medical Resident at the same institution (1994-1995). He obtained pulmonary and critical care training at the University of Wisconsin, Madison, WI, USA (1995-1998). In 1998, he joined King Abdulaziz Medical City, Riyadh, Saudi Arabia. He is currently the Chairman of the Intensive Care Department and the Medical Director, Respiratory Services. He served as a member of several institutional committees including being the member of several international committees for the Society of Critical Care Medicine (SCCM), American College of Chest Physician (ACCP), and a member of the administrative board of the Saudi Society of Critical Care.

 He received multiple grants and awards and has been an investigator on several multicenter international trials including the ADjunctive coRticosteriod trEatment iN criticAlly ilL patients with septic shock / RC12.059 (ADRENAL); Erythropoietin in Traumatic Brain Injury Study / RC10.063 (EPO-TBI); A Prospective Multicentre Randomized Controlled Trial of Early Goal Directed Sedation Compared with Standard Care in Mechanically Ventilated Patients in Intensive Care / RC-12-079 (SPICE III); Severe Acute Respiratory Infection Biological Sampling Study / RC13- 205-R (SARI); OSCILLATE Knowledge Translation – An Audit of ARDS Management / RC14/010 / MCT-04829; A multi-centre randomized controlled trial of an Open Lung Strategy Including Permissive Hypercapnia, Alveolar Recruitment and Low Airway Pressure in patients with acute respiratory distress syndrome (PHARLAP study) / CT13-005R; Prophylaxis of Thromboembolism in Critically ill Patients Using Combined Intermittent Pneumatic Compression and Pharmacologic Prophylaxis Alone: A Multicenter Randomized Controlled Trial (PTCP using CIPC & PPVPPA) / RC12/045/R (PREVENT); Middle East Respiratory Syndrome Corona Virus (MERS-CoV) RC13/244; MERS-CoV Infection Treated with a Combination of Lopinavir / Ritonavir and Interferon Beta 1B: A Placebo-Controlled, Double-Blind Randomized Trial (MIRACLE Trial) RC15-142-R among the several others.

He has more than 250 publications including articles in the New England Journal of Medicine (NEJM), JAMA, Lancet, and Critical Care Medicine. He has been a reviewer for more than 40 international journals as well as granting agencies.

Eng. Abdulrahman Alfaifi started his career in 1996 as a systems engineer working for SEMC and responsible for commissioning and operation of plasma based technologies, in 2001 he joined the RKH (now Prince Sultan Military Medical City)  as Senior Medical Physics Technical Officer and in charge of maintenance and calibration of various medical devices in OR, ICU and Pathology department.

In June 2005, Eng. Abdulrahman joined Ministry of National Guard Health Affairs where he has held several positions starting from Clinical Engineer, then as Director of medical Technology Assessment and Planning Unit, then as a Deputy Associated Executive Director of Clinical Engineering Department in charge of NGHA capital equipment tenders, medical technology assessment and planning, in addition to leading the activities of Medical Equipment Development Unit.

In March 2015, Eng. Abdulrahman Joined Barq Consulting Engineers as a project director and biomedical engineering consultant for KFMC project, leading a team of engineers from various disciplines to carry out the medical planning for PPNNCC (Proton and Particle therapy, National Neuro center and Cancer Centre) project.

Eng. Abdulrahman holds a bachelor’s degree in biomedical instrumentation from King Saud University and a Master degree in health and medical informatics and has several professional certifications and holds two patents in the field.

Turki Althunian is a senior scientific evaluator in the Directorate for Drug Evaluation at the Saudi food and Drug Authority (SFDA). Turki was trained as a pharmacist and epidemiologist. His work and research experience covers the assessment and the design of advanced clinical trials (e.g. non-inferiority trials, adaptive clinical trials, etc.) and the design of observational studies in the area of drug effectiveness and safety (mainly the utilization of real-world evidence in health care decision making with several publications). Turki works on the assessment of clinical development programs of drugs submitted for the approval in the Saudi market (especially biologicals). Additionally, his work covers the assessment of trials submitted for registration at the SFDA and participates as an active member in several internal and external scientific committees. He has a Bachelor of pharmaceutical sciences from King Saud University, a Master of clinical pharmacy from the University of Queensland (Australia), a Master of epidemiology and a PhD in pharmacoepidemiology and research methods from Utrecht University (the Netherlands).

With a Bachelor degree of Science in pharmacy from King Saud University, Riyadh 1991, a Master of Science degree in Clinical Pharmacy KSU, 1996. Further on completed Doctor of Pharmacy from university of Tennessee, USA 1999. And in 2009, completed Master of Science in medical Education, KSAU-HS, Riyadh.

Dr. Al Jeraisy participated in a number of workshops, and courses including American College of Clinical Pharmacy, Master class in Effective Leadership and Anti- Thrombosis Certificate program. As well as accomplished a number of publications.

He was appointed director of Clinical trial services, in addition to chairman of research office, King Abdullah International Medical research Center. As well as pediatric Clinical Pharmacy consultant, King Abdullah Specialized hospital. And Associated professor, Collage of pharmacy, King Saud Bin Abdulaziz University for health science.

• Head, Biomedical Ethics-King Abdullah International Medical Research Center, Ministry of National Guard – Health Affairs.
• Chairman – Institutional Review Board – Ministry of National Guard – Health Affairs.
• Consultant, National Committee for Bio and med Ethics and actively participate in writing the Saudi Research bioethics bylaws.
• Adjunct Assistant Professor, Bioethics, College of Public Health and Health Informatics, KSAU-HS.
• Chairman, Institutional Review Board, MNG-HA.
• Co-Founder of King Abdullah International Medical Research Center (KAIMRC) from the inception of the idea to its current state.
• Stake holder in the governance of research regulation in Saudi Arabia.

Dr. Manal Alaamery, is curently the Chairman of Innovation and Entrepreneurship Department (IED) and Head of the Developmental Medicine Department (DMD) at the King Abdullah International Medical Research Center (KAIMRC) at the Ministry of National Guard-Health Affairs (MNGHA). She is also the director of the satellite lab for the National Saudi Genome Program at KAIMRC, and a Principal Investegator at the Center of Exellence for Biomedicine (CEBM) at King Abdulaziz City for Science and Technology (KACST) and Brigham Woman’s Hospital (BWH) in association with Harvard Medical School. Formerly, she was an instructor at the Harvard Medical School and Children’s Hospital Boston.

As the chairman of IED, she is responsible for the ongoing Innovation activities at KAIMRC and the MNGHA. The IED was established in 2019 to serve the Kingdom’s vision 2030 and further enhance its resources and economic stability. Dr. Alaamery provides leadership in the identification and KAIMRC-wide adoption of innovation metrics to optimize KAIMRC’s research and innovation portfolio. Some of the IED activities include: creating Innovation and entrepreneurship programs specifications, documentation, and materials, registering patents, and trademarks at patent offices around the world, patent licensing and commercializing, maximizing research return on investment through supporting the creation of Spin-offs.

As the Head of DMD, Dr. Alaamery’s research investigates the causes of different genetics disorders such as understanding the genetic causes of Intelecultal disabilities and non syndromic congental heart defect in the Saudi population with the goal of identifing novel genes and therapeutic targets for rare disorders. In addtion, with the collobrators from BHW and KACST, she and her team are studying the role of sphingolipid metabolism in neurodegeneration to identify candidate targets for therapeutic intervention for different neurdegenrtaive disorders such as multiple sclerosis. Furthermore, Dr. Almaamery is intersted in developeing nanoparticles that can overcome the problems of drug delivery through oral or intravenous routes such as the difficult penetration of BBB, low bioavailability, short half-life and prolonged treatment in different diseases.

Dr. Alaamery received her clinical and postgraduate training at Harvard Medical School Genetics Program. She completed her clinical training at the Laboratory of Molecular Medicine (LMM) at Harvard focused on the areas of Hypertrophic and Dilated Cardiomyopathies, Neurological disorders, Muscular disorders, Hearing loss, Noonan spectrum, Pharmacogenetics. Dr. Alaamery also holds a Doctoral (Ph.D.) degree in Molecular Genetics/Biology from Boston College and a Master of Science degree in Clinical Microbiology from Thomas Jefferson University.

During Dr. Alaamery’s work and career, she has established herself as a research leader, and published in prestigious peer-reviewed scientific journals as well as patenting a number of novel ideas. Dr. Alaamery also taught several courses, led many initiatives and held several committee positions. In addtion, Dr. Alaamery is the recipient of several awards including the Dubai Harvard Foundation for Medical Research Award, Harvard Parteners In Excellence Award for team work, the Donald J. White Teaching Award at Boston College, and the Ambassador Award for academic excellance .

Dr. Mohamed Hussein is currently a senior research scientist and the chairman of the department of Biostatistics and Bioinformatics at King Abdullah International Medical Research Center, National Guard, Kingdom of Saudi Arabia. He has Over than 15 years of professional experience in biostatistics and bioinformatics with 10+ years in various leadership roles focused on building, mentoring and managing medium and large advanced analytics and data science teams. He has extensive working experience in the analysis and integration of high dimensional healthcare data sources such as electronic health records, insurance claims data, hospital records, disease registries and complex biological data. His research focuses on the application of advanced statistical and machine learning techniques such as Robust and regularized regression techniques, instrumental variable regression, propensity score and nested structural models, among others to a wide range of disease areas including cardiovascular disease, diabetes, and cancer. His research contribution has been published in several high impact journals among of which are diabetes care, American Journal of Respiratory Critical Care Medicine, and Value in Health. He served as former associate editor of the Journal of Infection and Public Health, and he is currently an active member of the American Statistical Association and the international society of Pharmacoeconomics and Outcomes Research.

Prior to joining KAIMRC Dr. Hussein has served at several technical and leadership roles among which a Principal of Real World Data Analytics at IQVIA (formerly known as IMS Health), a multibillion dollars healthcare consulting company based in USA; The director Biostatistics and predictive modeling at ValueMedics research, a healthcare analytics and consulting company, based in Virginia, USA.; and a senior biostatistician at the Research and Innovation Center, at Humana Inc., a large health insurance company based in Kentucky USA, where he was responsible for developing machine learning and predictive models for plan members risk stratification and predicting healthcare catastrophic events.

Dr. Hussein has attained multiple graduate degrees from university of Louisville which include doctorate of philosophy of biostatistics, Master of Science in public health with focus on decision science and a master of computer science and electrical engineering.

Dr. Alfadhel is currently Deputy Executive of King Abdullah International Medical Research Centre (KAIMRC). The Head of Genetics Division, Department of Pediatrics at King Abdulaziz Medical City, Riyadh, Saudi Arabia and associate professor at King Saud bin Abdulaziz University for Health Sciences (KSAU-HS). He is the director of medical genomic research laboratory at KAIMRC and established different innovative molecular genetic testing like whole genome sequencing and whole exome sequencing for example. Furthermore, he is the Editor in chief of journal of Biochemical and Clinical Genetics and editorial board member of four other journals for example: International Journal of Health Sciences, the Journal of Nature and Science of Medicine (JNSM), Frontiers in Pediatrics and Frontiers in Neurology journals.
He has published more than 115 research papers in the field of Genetics disorders in high impact factor journals for example New England Journal of Medicine, Nature Genetics etc… Additionally, he is authors of three books and chapter in other two books in the field of inborn errors of metabolism for example he wrote a chapter in the Physician’s Guide to the Diagnosis, Treatment, and Follow-up of Inherited Metabolic Diseases book.
He is also a Chair at the Newborn Screening Program at NGHA, member of credential committee board at Canadian College of Medical Geneticists (CCMG), member of Middle East Hyperammonemia and UCDs Scientific Group (MHUSG), member of and several international advisory boards, groups and committee. Dr. Alfadhel’s foresight and passion for innovation, earned him an award for inventing a new application in the Apple store and Google play for the treatment of inborn errors of metabolism Dr. Alfadhel’s current research interest is focused on studying genetic disorders related to inborn errors of metabolism and he contribute to discovery of >50 novel genes/diseases in the field of Genetic disorders.
Dr. Alfadhel received his bachelor degree in general medicine and surgery from King Saud University in Riyadh. He obtained his pediatric residency from King Abdulaziz Medical City in Riyadh and received the Pediatric Saudi Board certificate followed by Pediatric Arab Board certificate and the Canadian Board in Biochemical Genetics. In addition, he carries a Neurogenetics fellowship certificate and Master of Health Science (MHSc) in epidemiology.

Eng. Fuad Mosa is Vice President of SABIC’s Local Content & Business Development Unit – an arm of the company created to develop local content in the Kingdom according to KSA 2030 Vision.
He holds a Bachelor’s Degree in Chemical Engineering from KFUPM in Dhahran, a Master’s Degree in Chemical Engineering from KSU in Riyadh and an MBA degree from Thunderbird School of Management in Arizona, USA.
He has over 20 years of experience in deferent fields related to petrochemical industry. He contributes in more than 35 patents during his earlier years of experience in developing deferent Technology for SABIC.
He serves as board member at deferent companies, centers and institutions; He is currently the Chief Executive Officer of Nusaned Investment Company. Before appointed to his current role, he was serving as a General Manager of SABIC Global Chemical Technologies.

Dr. Majed Alghoribi is the Chairman of the Infectious Diseases Department at King Abdullah International Medical Research Center-Riyadh, Saudi Arabia. Dr Alghoribi has received his PhD in Infection, immunity, inflammation and repair from the University of Manchester, United Kingdom and completed his postdoctoral fellowship in microbial genomics and bioinformatics at Public Health England (PHE)-London, United Kingdom. His research interests are centring around epidemiology, prevention and transmission of antimicrobial resistance. He recognized the need to develop better AMR monitoring and surveillance program thought “one health” approach using the power of next-generation sequencing, applied bioinformatics and public health microbiology. This will help to understand the mechanisms of resistance, modes of transmission, dissemination and prevention of clinically and public health relevant pathogens.

The Infectious disease research department (IDRD) is a prime department at King Abdullah International Medical Research Center. The IDRD is divided into the following units i) ‎‎Microbial Genomics and AMR Unit ii) Virology and Vaccine Development unit iii) Biosafety Level 3 laboratory (BSL3). The department is dedicated to enhancing prevention and treatment of infectious diseases through diversified basic, translational, and clinical research activities, surveillance programs and reference laboratory services. This will be seamlessly integrated with education and training development to become the next generation of leaders in this field and attracting interdisciplinary national and international collaborators.

Dr. Mohammad Bosaeed is currently working as an Infectious Diseases Consultant at the Ministry of National Guard Health Affairs. He obtained his MBBS degree at King Abdulaziz University, Jeddah, KSA. He completed his Internal Medicine residency and adult Infectious Diseases Fellowship Training at King Abdulaziz Medical City, Riyadh, KSA. Dr. Bosaeed has a particular interest in Transplant Infectious Diseases, where he was granted a one-year clinical fellowship at the University of Toronto, Ontario, Canada.
After he completed his training in Canada, he joined as a consultant in Infectious Diseases in King Abdulaziz Medical City, Riyadh
At KAIMRC Dr. Bosaeed is the Principle Investigator of the first phase I clinical trial” A phase I clinical trial to determine the safety and immunogenicity of the candidate MERS-CoV vaccine ChAdOx1 MERS in healthy adult volunteers in Saudi Arabia”.

Osman Hashim is a Veterinary Surgeon who introduced to the research field as a researcher at Animal Resources Research Corporation (ARRC), Sudan. He had had studies animals’ vaccinology, virology and veterinary immunology as former researcher in ARRC. Joining Ministry of Water, Environment and Agriculture (MEWA), Saudi Arabia as virology specialist boosts his contributions in veterinary research field by comparing research findings with applied veterinary medicine. In his current position at MEWA, he has been responsible for planning and implementing of animal diseases’ control strategies. One of the highlights from his current job is the implementation of the first epidemiological studies on MERS-CoV. He contributed recently as co-investigator in KIMARC research number (RC16/093/R) under the title “Evaluation of Adenoviral Vector-based MERS-CoV vaccine in dromedary camels in Saudi Arabia”. You can contact him by email at ohosmanibrahim@gmail.com.

Coming Soon

• Engineer (ENSTA), and MBA Wharton
• Former strategy consultant at Booz, Allen & Hamilton and former Head of Corporate Development at Carrefour
• President of AFIRMM, French association leading research on mastocytosis
• Co-inventor of more than 50 patents filed by AB Science
• Founder of AB Science SA, Alain Moussy holds the position of Chairman for Association Française pour les Initiatives de Recherche sur, Chairman, CEO & Scientific Director at AB Science SA and Chairman for AMY SAS.
• In his past career Mr. Moussy held the position of Head-Corporate Development at Carrefour SA.
• Mr. Moussy received an MBA from The Wharton School of the University of Pennsylvania and an undergraduate degree from Ecole Nationale Supérieure de Techniques Avancées.

Ketan’s background spans 15 years of experience working in industry at Lilly, Pfizer, Oracle HSGBU and most recently at Astrazeneca. Ketan studied computer engineering and AI (MSc from Edinburgh), after which he did a PhD in Bioinformatics (Oxford). Over the years Ketan has led and worked on data science projects in the industry from early stage drug discovery through to clinical development, product launch and medical affairs. At Oracle Ketan worked in pre-sales before moving to product strategy for Precision Medicine applications. More recently he was a Health informatics Director working on Big Health data (claims, EHRs, digital, genomics etc.) for AstraZeneca to optimise clinical trials, product launch and post-marketing and life cycle management. Before joining Clarivate, Ketan was an industry consultant working with Life Sciences companies at Teradata on large data and analytics projects.

Coming Soon

• Medical Doctor with specialization in Pharmaceutical Medicine
• 32 years experience in Health Care Industry
• mMBA Wharton/INSEAD
• Former Chief Medical Officer and Innovation/R&D Head for “Emerging Markets” at Sanofi
• Former Global Head Regulatory Affairs CHC at Roche
• Former country medical director for different groups in several European countries

Competencies:

• Expert in Medical Affairs, Emerging Markets, Drug Development( Industrial , Preclinical & Clinical), Innovation, External Partnerships and Management
• From Medical Devices to Pharma (both prescription medicines and Consumer Health Care)
• Across Medical Affairs functions (from Medical to Regulatory passing by Market Access, R&D …) and beyond (Business, Marketing, Innovation )
• Experience both at country level (Belgium, The Netherlands, and Spain) and corporate level (Global and Emerging Markets)

Career Summary:

• Global CMO, AB Science
  • Vice-President & Global Head of Innovation –Value Added Medicines Innovation Centre-Sanofi Global BU General Medicines & Emerging Markets(GEM)
  • Vice-President Emerging Markets Innovation & Search Unit/EMISU-Sanofi Global Ops & R&D
  • VP/ Chief Medical Officer & R&D Head –Sanofi Intercontinental
  • Medical, Clinical and Scientific Affairs Director Sanofi-Aventis Belgium
  • Senior Medical Director-Aventis Spain
  • Medical Director-Aventis Belgium
  • Medical Director-Sanofi-Synthelabo Belgium
  • Director of Clinical Research, Medical and Regulatory Affairs-Synthelabo Belgium
  • Head of International Regulatory Affairs and Rx to OTC Switches Project Director

• Roche Consumer Health World-wide
  • Medical Manager & Business Therapy Area Coordinator( BU Head)-Roche Belgium
  • Director of Medical, Clinical & Regulatory Affairs-Syntex Benelux
  • Scientific & Regulatory Affairs Officer-3M Health Care Belgium
  • Medical practices

• Expertise Clinical Chemistry / Metabolic Medicine
• Memberships Fellow Royal College of Physicians of Ireland 2004
• Member Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom 2012
• Fellow Royal College of Pathologists 2001 (emeritus 2010)
• Other Relevant Information UK representative on Blood Products Working Party
• UK representative on Committee for Advanced Therapies

Dr. Yon Su Kim had his Phd from Seoul University College of Medicine in 1996. Dr. Kim has had long working experience varied in different fields. He started as an Assistant Professor in 1999 and now working as a President and CEO of Seoul National University Hospital. Some of Dr. Kim’s academic activities are General Secretary, Korean Society of Nephrology, Seoul, Korea; Director, Board of External Affairs and Cooperation; Director, Board of Academic Affairs Korean Society of Nephrology, Seoul, Korea; Director, Board of Planning Korean Society of Nephrology, Seoul, Korea and President Korean Society of Nephrology, Seoul, Korea. He is also a member in Korean society of Nephrology, Korean Society of Organ Transplantation, American Society of Nephrology, American Society of Transplantation, International society of Nephrology.

Ersen Gokser is molecular biologist by education and graduated from Middle East Technical University Biological Sciences, Ankara, Turkey. Ersen is currently working as Senior Manager, Development Operations at Amgen. He pursued a career in pharmaceutical industry and started to work in clinical research area at Eli Lilly & Company in 2003 as a Clinical Research Associate. Ersen took the position of Area Quality Coordinator role for medical department of Lilly Turkey in 2004. After one year, his area of responsibility expanded to cover Romania, Bulgaria, Croatia and Slovenia and he was promoted to the role of Area Quality Consultant in 2007. He was promoted to the role of Clinical Research Manager in 2007 and continued to work for Lilly until 2009. During 2009-2013, he worked as Clinical Operations Manager for Abbott, Business Operations Lead for Pfizer and Clinical Operations Manager at Novo Nordisk before joining Amgen.

He is currently acting as Country Network lead for TransCelerate Inc. in Turkey. He was also an active member of the GCP Committee at Association of Research-Based Pharmaceutical Companies and served as Vice Chairman of the committee for the periods 2009-2010 and 2012-2019.

Sanjeev Gupta graduated from the university of Calicut with a Degree in Electrical Engineering and has a strong background and experience in the implementation of heavily IT driven solutions this brought him to software engineering in 1998, when he joined a Belgian healthcare company.  This led to a close collaboration with IBM”s R&D labs in Rochester, Minnesota and IBM Global Services Belgium.  Thereafter he moved on to work for AIS Systems  (VAtech, Austrian based Steel Technology company – software development in the areas of automating complex regulated research in production environments and planning systems). In 2004 Sanjeev took another step forward by setting up his own IT company, providing consultancy services to pharmaceutical and bio-technology companies in Europe and the US.

Sanjeev has gained a good reputation amongst his peers as a solid developer and in the conceptualization and design of best-in-class software solutions, based on leading-edge technology, today he leads Arisglobals Eclincal solutions team in Europe out of Belguim and is involved in all aspects of CTMS and Eclinical

Gjon Mirdita is a Doctor of Dental Medicine by training, with more than 18 years of experience in the Pharmaceutical and Clinical Research industries, fulfilling various roles in Clinical Operations, Regulatory and Start-up and Medical Affairs. He is experienced in leading large international, cross-functional teams and has a passion for providing and accelerating access to new treatments for patients in need.

Walter (Wally) Klemp is the Chairman and CEO of Moleculin Biotech, Inc., a Nasdaq-listed (Nasdaq: MBRX) drug development company based in Houston, Texas.

Mr. Klemp helped facilitate an initiative similar to Saudi Arabia’s Vision 2030 in the country of Poland. This was called “Vision 2020,” and it’ objective was to help diversify Poland’s economy by establishing Poland as a hub for new technology, with an emphasis on biotechnology, throughout Eastern Europe. Specifically, Moleculin, which had been developing technologies discovered at MD Anderson Cancer Center (the world’s largest cancer research center), sublicensed cutting edge cancer drug technologies to development companies in Poland (including rights to surrounding territories) in exchange for access to grant funding intended for their Vision 2020. This led directly to the expansion of clinical trial activity in Poland.

As a comparison, Saudi Arabia and Poland are both similar in population, have well-established medical infrastructures and are geographically positioned to provide leadership throughout their respective regions. In contrast, however, today there are approximately 4 times as many clinical trials just in the city of Warsaw as there are in the entirety of Saudi Arabia. Mr. Klemp proposes to help Saudi Arabia facilitate its Vision 2030 in much the same way as Poland, through the dramatic expansion of clinical trial activity by jump-starting Saudi Arabia’s access to new technologies through in-licensing activities.

Mr. Klemp is the Founder and Chairman of two current Nasdaq-listed biotech companies (MBRX, SOLY), one in cancer drug development and one in medical devices. With 17 years in the biotechnology industry, he has been responsible for numerous clinical trials, as well as regulatory approvals of both drugs and devices and out-licenses to EU and Asian drug companies. He has raised over $.75 billion in development stage funding for his companies, including 7 public securities issuances and 4 Nasdaq IPOs. Mr. Klemp’s first company became #1 on the INC 500 List of America’s Fastest Growing Companies, as well as earning the American Marketing Association’s Gold Edison Award. He was invited to serve as an Advisor to the White House Conference on Small Business and has delivered numerous lectures on the development of the biotechnology sectors.

Dr. Ayach is Senior Director with GE Healthcare & Partners, EGM. He specializes in both corporate and government sector to help address key strategic and operational challenges related to long term strategy design and development, leading and managing transformational projects, market feasibility, entrepreneurship and value development. He brings over 17 years of consulting experience across Europe and the Middle East, in which he worked with top executives and decision makers where he provided expertise in business growth strategies, business incubation and internationalization, Healthcare performance optimization, strategy design, value based Healthcare, smart health system engineering and IT integration, PPP’s, Medical tourism and overseas treatment strategies, business and operation modelling, market access and greenfield hospital planning and implementation.

He received the European Executive Award for enterprise engineering and consulting in business internationalization strategies for small and medium enterprises, by the National Center of Research, Italy. He has various working papers, book chapters and international publications on topics such as efficiency modelling and innovation in the Healthcare sector, and he is member at the European Decision Science Institute.

Ali has the following educational qualifications:

• Post Doctorate in Decision Science
• Ph.D. in Management and Enterprise Engineering University of Rome 2, Italy & Harvard University, USA
• ECE, Leadership and Conflict Resolution, Harvard University, USA
• MBA , Enterprise Engineering , Rome 2 , Italy
• Master in Bio-Robotics Engineering , Rome La Sapienza , Italy
• B.Eng. in Mechanical Engineering, Rome La Sapienza, Italy

Prior to GE Healthcare & Partners , Ali worked at Philips Consulting where he supported in developing the Healthcare practice and led successfully multiple organizational engagements in the Middle East. He supported clients including Healthcare regulators and Operators, and research centers, and fulfilled variety of consulting roles in which he led large transformation programs such as system wide outpatients and surgical transformation, performance and productivity improvement, data analytics, and IT system integration architecture review , including transformation orchestration, capacity planning, workflow optimization and clinical service modeling, and launch of new medical facility. Prior to Philips Consulting, he has served in senior advisory roles with Dubai Government, including Health Authorities.. Ali has also worked with Accenture based in Europe on a variety of strategic and operational projects in healthcare including: M&A, health technology assessment, process re-engineering, and decision analysis with a focus in policy implementation, change management and integration. He also has experience working as a researcher and assistant professor at the University of Rome, Faculty of Management Engineering.

Jamal is a dynamic business leader with 24+ years of high caliber experience in management consulting, healthcare, regulatory affairs and compliance, healthcare IT, medical devices, and business management in the Middle East and USA. He has worked in several geographies, including KSA, UAE, Bahrain, Jordan, and USA. He is intimately familiar with GCC culture, future outlook, and opportunities for development. He has worked across several consulting competencies (Performance Improvement, risk, IT Advisory), all with successful results.

He has managed engagements in several sectors (i.e. P&U, Telco, AAIC, Healthcare), for government and private clients. He worked in the industry and has wealth of knowledge with respect to clients’ needs. In terms of healthcare strategy and reform, he has helped clients articulate and understand their strategies at the department, entity and systems levels.

Jamal was columnist for Arab Health Magazine; “Expert Opinion” and a speaker at the Life Sciences Foresight series hosted by Dubai Science Park.
Jamal has in depth knowledge is several quality management systems, including ISO, CE-MARK, TUV, etc. and successfully obtained compliance certifications, in line with these systems, for several entities